Systemic lupus erythematosus associated with paclitaxel use in the treatment of ovarian cancer.
Over the last years, scleroderma-like skin changes have been reported with two of the taxanes, docetaxel and paclitaxel, but specific antibodies were not found in any of those cases. Recently, paclitaxel was linked to cutaneous lupus erythematosus in two cancer patients, showing high titers of serum anti-Ro (SS-A) antibody. To our knowledge, this is the first known case of a patient with serologically confirmed systemic lupus erythematosus secondary to paclitaxel use.
Dasanu
Constantin A
CA
Seattle Hematology-Oncology, Seattle, WA 98466, USA. c_dasanu@yahoo.com
Alexandrescu
Doru T
DT
D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced* / Q000503:physiopathology; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy; D017239:Paclitaxel / Q000009:adverse effects* / Q000627:therapeutic use
D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel